Neurology: A new drug for multiple sclerosis that slows brain atrophy

Ibudilast is a small molecule of pdesterase (PDE) inhibitors that inhibit PDE3A, PDE4, PDE10, and PDE11, and has additional inhibitory effects on macrophage inhibitors and tooll-like subject 4.
phase 2 placebo-controlled trial in 297 patients with relapsed remission-relieving multiple sclerosis (MS) did not find any benefit to annualized recurrence rates or new MRI lesions.
, at 12 months, the percentage change in brain volume (PBVC) in patients taking a dose of 60 mg was observed to be reduced by 33% (P-0.04).
analysis showed that people who took doses of 60 mg (0.14; p-0.004) and 30 mg (0.17; p-0.036) had a lower proportion of new lesions that evolved into persistent cavity gaps than those assigned to placebos (0.24).
studies have shown that disability progresses less for those who have been receiving active treatment for two years.
Because these results are beneficial for brain atrophy, tissue integrity, and disability, the NeoNEXT 102/2 and Primary Progress Iudilast NeuroNEXT trials (NN102/SPRINT-MS) were conducted in patients with multiple sclerosis progression.
PRINT-MS, conducted by Robert T Naismith of the University of Washington and others, was a 96-week clinical phase 2, placebo-controlled, multi-center, randomized, double-blind, parallel group trial designed to assess the efficacy and safety of Iudilast's treatment of primary and secondary progressive MS at doses of 60 to 100 mg per day.
the main endpoint, total brain atrophy as measured by the brain's substantial fraction (BPF).
results showed that 129 participants were treated and 126 were treated as placebo control groups.
new or expanded T2 lesions were observed in 37.2 per cent of Ibdirast and 29.0 per cent of placebos ( P - 0.82).
T1 low-density lesions were observed at 96 weeks, with 33.3 per cent in Ibdirast and 23.5 per cent in placebo (p - 0.11).
35% less graysum atrophy (p - 0.038) than in the control group.
Ibudilast group's progression of total brain atrophy was 20% slower than that of placebos (p s 0.08).
the main significance of the study was the discovery that Iudilast therapy was associated with a decrease in grayscatrophy.
Ibdirast therapy was not associated with a decrease in new or expanded T2 lesions or new T1 lesions.
's effect on brain volume confirms the previous conclusion that Iudilast appears to affect markers associated with neurodegenerative processes, but does not affect inflammatory processes.
original origin: Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study, Robert T. Naismith, Robert A. Bermel, et al., on behalf of the SPRINT-MS Investigators Neurology Jan 2021, 96 (4) e491-e500; DOI: 10.1212/WNL.00000000000011314Freeman Source: MedSci Original Copyright Notice: All noted on this website "Source: Metz Medicine" or "Source: MedSci Original" text, images and audio and video materials, copyrights are owned by Metz Medical, without authorization, no media, website or individual may reproduce, authorized to reproduce with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here